Babak Moghimi

University of Southern California — United States

Medicine · Health Sciences

13h-index1.2kcitations54works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(35), Virus-based gene therapy research(8), Viral Infectious Diseases and Gene Expression in Insects(8), Hemophilia Treatment and Research(6), Neuroblastoma Research and Treatments(6)

Publications54 total

Extracellular Matrix Topography Drives Adrenergic to Mesenchymal Transition in Neuroblastoma
Advanced Materials·2025· 1 citedOpen Access
Long-term survival after luveltamab tazevibulin, a novel folate receptor-α (FRα) targeting antibody drug conjugate (ADC) in children with CBFA2T3::GLIS2 acute myeloid leukemia (AML).
Journal of Clinical Oncology·2025
Supplementary Figures from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
2025Open Access
Supplementary Data 1 from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
2025Open Access
Data from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
2025Open Access
CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
Blood Cancer Discovery·2024· 10 citedOpen Access
TBL1 Inhibition Eradicates Drug Resistant Leukemia Initiating Cells in T-ALL
Blood·2024Open Access
297 Preclinical development of CTSR-Armored B7H3 CAR-T cells for pediatric solid tumors
Regular and Young Investigator Award Abstracts·2024Open Access
Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML
Blood·2023· 2 cited
Figure S7 from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
Figure S6 from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
Figure S6 from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
Figure S4 from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
Figure S5 from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
Figure S2 from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
Data from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
Data from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
Figure S1 from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
Supplemental Figure Legends from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
Figure S2 from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Sarah A. Richman(17), Selene Nuñez-Cruz(17), Lucy Z. Li(17), Zachary T. Gershenson(17), Zissimos P. Mourelatos(17), Stephan A. Grupp(17), Michael C. Milone(17), David M. Barrett(11), Roland W. Herzog(11), Shahab Asgharzadeh(9), Sakunthala Muthugounder(8), Deepa Bhojwani(8), David M. Barrett(7), Yong‐Mi Kim(6), Chintan Parekh(6), Samy Jambon(5), Ou Cao(5), Jörg Bungert(5), Irene Zolotukhin(4), Brandon K. Sack(4)